E-cadherin as a predictive marker of brain metastasis in non-small-cell lung cancer, and its regulation by pioglitazone in a preclinical model
Journal of Neuro-Oncology, 05/14/2012Yoo JY et al.
The authors found that E–cadherin expression was proportional to pioglitazone exposure time. Interestingly, pioglitazone pretreatment before cancer cell inoculation prevented loss of E–cadherin expression and reduced expression of MMP9 and fibronectin, compared with the control group. E–cadherin expression could be a predictor of brain metastasis in patients with non–small–cell lung cancer (NSCLC). Preventive treatment with pioglitazone may be useful for modulating E–cadherin expression.
MDLinx connects healthcare professionals and patients to tomorrow's important medical news, while providing the pharmaceutical and healthcare industries with highly targeted interactive marketing, education, content, and medical research solutions.